AHA 2024 - Subodh Verma shares the results of a sub-analysis from the SELECT trial in patients who had a prior history of CABG.
Semaglutide reduces MACE in patients with obesity or overweight and prior CABG
Share
Save
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Overview
Educational information
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Faculty
Prof. Subodh Verma is cardiac surgeon at St. Michael's Hospital and professor at the University of Toronto in Toronto, ON, Canada.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 19 November 2024
Recommended
Details
Presenters
Overview
AHA 2024 - Subodh Verma shares the results of a sub-analysis from the SELECT trial in patients who had a prior history of CABG.
Educational information
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Faculty
Prof. Subodh Verma is cardiac surgeon at St. Michael's Hospital and professor at the University of Toronto in Toronto, ON, Canada.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 19 November 2024
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?